Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 20/20 | 0.85 |
| ▸ | TTK | P33981 | 10/20 | 0.85 |
| ▸ | AURKA | O14965 | 1/20 | 0.79 |
| ▸ | CSF1R | P07333 | 2/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.77 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.77 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.77 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.77 |
| ▸ | ATM | Q13315 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23625483 | 0.94 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625300 | 0.94 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23611088 | 0.94 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625297 | 0.94 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625296 | 0.94 | PRKDC (0.90) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL20330484 | 0.92 | PRKDC (1.00) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL20358252 | 0.92 | PRKDC (1.00) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL29770931 | 0.92 | PRKDC (1.00) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL20358847 | 0.92 | PRKDC (1.00) | PRKDCTTKAURKACSF1RPIK3CD | |
| SCHEMBL23625476 | 0.91 | PRKDC (0.79) | PRKDCTTKAURKACSF1RPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300977-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | INTELLIA THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| CN-117940426-A | DNA-dependent protein kinase inhibitors, compositions and uses thereof | 英特利亚治疗股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4323360-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | Intellia Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221696-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | INTELLIA THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2021136461-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | 成都百裕制药股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300977-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | CHEK1, DCK, CHEK2 | PRKDC 4/4885TTK 68/4885AURKA 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.